Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Equillium to Participate in Oppenheimer’s 2026 Innovation on the Island Event

globenewswire.com
EQ The article announces Equillium's participation in an upcoming investor event. It provides a brief overview of the company and its lead therapeutic candidate, EQ504. No specific performance indicators or future outlook are discussed, making the sentiment neutral.

Equillium to Participate in Oppenheimer’s 2026 Innovation on the Island Event LA JOLLA, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will be presenting at Oppenheimer’s 2026 Innovation on the Island Event on Tuesday April 28, 2026 at 7:50am AST.

Members of the Equillium management team will be available to meet with investors who are registered to attend the conference.

About Equillium

Equillium is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders. The company’s lead therapeutic candidate is EQ504, a potent and selective aryl hydrocarbon receptor (AhR) modulator designed with a multi-modal, non-immunosuppressive mechanism of action to be complementary to other inflammation and immunology agents. EQ504 is an investigational therapeutic program with potential for targeted, local delivery via enteric coating for the treatment of ulcerative colitis and other gastrointestinal diseases or inhaled formulations for the treatment of inflammatory lung diseases.

For more information, visit www.equilliumbio.com.

Investor Contact

PJ Kelleher

LifeSci Advisors, LLC

+1-617-430-7579

pkelleher@lifesciadvisors.com